By Catherine Knowles, C3’s Director of Policy
Democratic Senator Ben Nelson (NE) announced this afternoon that he will vote for cloture on the motion to proceed Saturday.
Continue reading to see exactly what Senator Nelson said, and for additional updates on the pending vote. Read the rest of this entry »
By Catherine Knowles, C3’s Director of Policy
On Thursday afternoon, Senate Majority Leader Reid (NV) set the procedural wheels in motion for a vote on the Patient Protection and Affordable Care Act.
The first procedural vote is expected around 8pm on Saturday. It will be a cloture vote on the motion to proceed. Majority Leader Reid is working to line up the 60 votes needed to pass the cloture motion (a cloture motion must be approved by three-fifths of the Senate).
Continue reading for more information on the upcoming Senate vote as well as a summary of some of the provisions included in the Senate bill that C3 thinks are important for people living with colorectal cancer. Read the rest of this entry »
By Nancy Roach, the Founder of C3 and Chair of its Board of Directors
A National Cancer Institute (NCI) working group has developed recommendations about how to engage advocates effectively in NCI research activities. The recommendations are open to public comment until November 30, 2009. Rather than go into detail about the recommendations, I will explain from my personal experience why I feel they are important and present C3’s feedback. Read the rest of this entry »
Picoplatin can be as effective as oxaliplatin as an initial treatment for advanced colorectal cancer but has less neuropathy.
Updated information comparing picoplatin in combination with 5-FU and leucovorin (FOLPI) to the standard oxaliplatin treatment (FOLFOX) found similar response rates. About half of patients on both treatments were alive a year later. However, there was significantly less neuropathy overall with FOLPI and no severe neuropathy.
FOLPI did have substantially more serious problems with lowered blood counts than FOLFOX. Read the rest of this entry »
Colorectal cancer patients 65 and older without other serious medical problems benefitted when Avastin® (bevacizumab) was added to chemotherapy.
Combining results of four randomized clinical trials of Avastin and chemotherapy in patients with advanced colorectal cancer, researchers found that adding Avastin increased both the time older patients lived and the time before their cancer got worse.
Patients who were 70 and older had similar improvements. Read the rest of this entry »
